Lyka Labs Ltd Stock Price Today (NSE: LYKALABS)
Fundamental Score
Lyka Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lyka Labs Ltd share price today is ₹66.74, down 2.00% on NSE/BSE as of 7 August 2026. Lyka Labs Ltd (LYKALABS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹252.38 (Cr). The 52-week high for LYKALABS share price is ₹109.00 and the 52-week low is ₹44.10. The company has a Return on Equity (ROE) of -10.24% and a debt-to-equity ratio of 0.53.
Lyka Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Lyka Labs Ltd share price chart: -18.75% return over the past month. 52-week high ₹109.00, 52-week low ₹44.10.
Lyka Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹68.10 | ₹68.10 | ₹66.74 | ₹66.74 | 6.04K (Cr) | |
| ₹72.00 | ₹72.45 | ₹68.00 | ₹68.10 | 9.03K (Cr) | |
| ₹66.66 | ₹69.99 | ₹66.66 | ₹69.99 | 38.74K (Cr) | |
| ₹63.84 | ₹67.03 | ₹63.00 | ₹66.66 | 20.76K (Cr) | |
| ₹60.80 | ₹63.84 | ₹60.30 | ₹63.84 | 26.59K (Cr) | |
| ₹58.87 | ₹60.99 | ₹58.23 | ₹60.80 | 10.62K (Cr) | |
| ₹59.77 | ₹60.43 | ₹58.00 | ₹58.89 | 61.80K (Cr) | |
| ₹61.19 | ₹62.45 | ₹59.00 | ₹59.87 | 40.72K (Cr) | |
| ₹64.41 | ₹66.20 | ₹61.19 | ₹61.71 | 37.75K (Cr) | |
| ₹63.99 | ₹65.40 | ₹63.50 | ₹64.41 | 8.34K (Cr) |
Lyka Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹60.80 | ₹72.45 | ₹60.30 | ₹66.74 | +9.77% | |
| ₹74.81 | ₹77.00 | ₹58.00 | ₹60.80 | -18.73% | |
| ₹60.48 | ₹77.05 | ₹54.65 | ₹73.95 | +22.27% | |
| ₹59.75 | ₹67.99 | ₹57.00 | ₹58.30 | -2.43% | |
| ₹45.80 | ₹61.99 | ₹45.80 | ₹59.70 | +30.35% | |
| ₹62.08 | ₹62.38 | ₹44.10 | ₹44.95 | -27.59% | |
| ₹72.30 | ₹73.85 | ₹60.20 | ₹62.35 | -13.76% | |
| ₹75.10 | ₹84.70 | ₹70.21 | ₹71.74 | -4.47% | |
| ₹79.99 | ₹86.90 | ₹72.20 | ₹75.89 | -5.13% | |
| ₹94.04 | ₹96.00 | ₹79.06 | ₹80.42 | -14.48% | |
| ₹96.67 | ₹100.94 | ₹91.58 | ₹94.04 | -2.72% | |
| ₹101.40 | ₹102.55 | ₹93.00 | ₹96.07 | -5.26% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap pharma play attempting a turnaround through merger, but financials are weak and valuation is stretched; avoid until concrete improvement.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Lyka Labs has seen a mixed bag of news. On March 16, 2026, NCLT approved the merger of Lyka Exports with Lyka Labs. However, Lyka Labs clarified on April 9, 2026, that there were no material events behind the recent share price movement. The stock hit a 52-week low of on March 30, 2026, amidst a broader market recovery.
CORE STORY (THE REAL GAME)
Lyka Labs is a micro-cap pharma play attempting a turnaround through corporate restructuring (merger with Lyka Exports) while battling profitability concerns and market skepticism.
- NCLT approved merger with Lyka Exports
- Weak Q3 FY26 results with declining revenues and profits
- Stock at 52-week low amidst broader market recovery
- Successful integration of Lyka Exports
- Significant improvement in quarterly earnings
- New order wins or partnerships
- Micro-cap liquidity risk
- High debt-to-equity ratio
- Stretched valuation compared to industry peers
FII holding is negligible (0.17%), DII holding is also low (0.66%), indicating limited institutional interest.
Indian pharma sector projected to reach $130 billion by 2030, but faces global pricing pressures and supply chain issues.
Yes - Free Cash Flow 5Y: ₹76.65 Cr
Next 3-6 months hinge on successful merger integration and improved financial performance. Watch for signs of revenue growth and profitability.
Primary Thesis Risk
Inability to successfully integrate Lyka Exports and improve profitability will lead to further downside.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lyka Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lyka Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LYKALABS across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Operating Margins (22.24%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Cash Generation (₹63.22 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (58.16%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (-10.24%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-6.10%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-529.94%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-16.15%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (4.19% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.77% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-2.73x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.95%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lyka Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lyka Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lyka Labs LtdLyka Labs Ltd...Selected✓ LYKALABS • 500259 | 18.9/100 | ₹66.74₹67 | ₹252.38₹252.38 | — — | -10.24%Poor -10.24% Poor | -6.10%Poor -6.10% Poor | 0.53Good 0.5 Good | 0.77%Average 0.77% Average | 8.29%Good 8.29% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Lyka Labs Ltd PE Ratio History
Historical price-to-earnings ratio for LYKALABS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.25 | ₹75.89 | 33.7x |
| FY 2022 | ₹13.57 | ₹129.70 | 9.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lyka Labs Ltd Quarterly Performance
Latest quarterly metrics for LYKALABS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-16.15%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-529.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.29%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.77%
Compounded annual net profit growth over 5 years
Lyka Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LYKALABS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lyka Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Lyka Labs Ltd (LYKALABS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Lyka Labs Ltd
About LYKALABS (Lyka Labs Ltd)
Lyka Labs Ltd is a dynamic pharmaceutical entity deeply rooted in the Indian landscape, operating at the intersection of innovative drug development and robust manufacturing practi...ces. With a firm commitment to healthcare advancements, the company meticulously crafts a diverse portfolio of pharmaceutical formulations and active pharmaceutical ingredients (APIs), addressing a spectrum of therapeutic needs. Lyka Labs dedicates significant resources to research and development, constantly seeking to refine existing products and pioneer novel solutions that contribute to improved patient outcomes. The company's operational strategy focuses on maintaining rigorous quality control measures throughout the entire production process, from raw material sourcing to final product distribution, ensuring safety and efficacy. By fostering a culture of scientific excellence and ethical business practices, Lyka Labs is poised to continue its growth trajectory within the ever-evolving pharmaceutical sector. The company’s diverse product line demonstrates its commitment to catering to varied health and wellness requirements. Their formulations encompass a range of therapeutic areas, featuring specialized skincare solutions designed to soothe, protect, and rejuvenate. From gentle emollients and targeted topical steroids to potent antifungal and antibacterial treatments, Lyka Labs addresses common dermatological concerns with precision. Beyond skincare, the company also offers effective acne management therapies, pain relief medications, and scientifically formulated anti-aging products. Additionally, their range extends to essential personal care items such as cleansing lotions, hair care products designed to combat dandruff, and sunscreens for sun protection, reflecting a dedication to overall well-being and preventative healthcare. Lyka Labs' product development philosophy emphasizes both efficacy and safety, utilizing advanced formulations and rigorous testing protocols. Lyka Labs' strategic vision involves expanding its reach and impact within the pharmaceutical market. This expansion encompasses strengthening existing product lines through continuous innovation and strategic partnerships to introduce new and effective therapies to the market. The company places a strong emphasis on building lasting relationships with healthcare professionals and stakeholders, ensuring that their products are readily accessible to patients who need them. With a robust infrastructure, a skilled workforce, and a dedication to ethical business practices, Lyka Labs is well-positioned to navigate the complexities of the pharmaceutical industry and achieve sustainable growth. Through its commitment to quality, innovation, and patient-centric care, Lyka Labs remains a key player in shaping the future of healthcare in India and beyond.
Company Details
Key Leadership
LYKALABS Share Price: Frequently Asked Questions
What is the current share price of Lyka Labs Ltd?
Lyka Labs Ltd (LYKALABS) trades at ₹66.74 on NSE and BSE. Market cap ₹252.38 (Cr). Educational data only.
What is the P/E ratio of Lyka Labs Ltd?
Lyka Labs Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Lyka Labs Ltd?
Lyka Labs Ltd has a Bull Run score of 18.9/100 based on 25+ financial parameters.
Does Lyka Labs Ltd pay dividends?
Lyka Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Lyka Labs Ltd?
Lyka Labs Ltd has ROE of -10.24%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lyka Labs Ltd?
Lyka Labs Ltd has debt-to-equity of 0.53.
Is Lyka Labs Ltd a good investment?
Bull Run gives Lyka Labs Ltd a score of 18.9/100. This is not investment advice — consult a SEBI-registered advisor.